Inspirna Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
15
- Latest Deal Type
-
2ndary - Private
- Investors
-
11
Inspirna General Information
Description
Developer of cancer therapeutics designed for the treatment of previously untreatable common cancers. The company's technology utilizes a proprietary discovery platform and microRNA mapping to identify unknown cancer drivers, enabling oncology patients to access oral small molecules and antibody-drug conjugates that target drivers of metastasis.
Contact Information
Website
www.inspirna.comCorporate Office
- 30-02 48th Avenue Long Island City
- Suite 350
- New York, NY 11101
- United States
Corporate Office
- 30-02 48th Avenue Long Island City
- Suite 350
- New York, NY 11101
- United States
Inspirna Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 8. Later Stage VC (Series D) | 29-Aug-2022 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC (Series C) | 24-Feb-2021 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC (Series C) | 09-Oct-2018 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series B) | 03-Jun-2016 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A) | 31-Jul-2015 | Completed | Pre-Clinical Trials | |||
| 3. Grant | 11-Aug-2014 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 30-Sep-2013 | $2.5M | $2.5M | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 01-Jan-2010 | Completed | Startup |
Inspirna Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A | 13,889,841 | $0.000100 | 8% | $0.61 | $0.61 | 1x | $0.61 | 2.79% |
| Seed | 5,869,618 | $0.000100 | 8% | $0.53 | $0.53 | 1x | $0.53 | 1.18% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Inspirna Comparisons
Industry
Financing
Details
Inspirna Competitors (24)
One of Inspirna’s 24 competitors is Attune Pharmaceuticals, a Venture Capital-Backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Attune Pharmaceuticals | Venture Capital-Backed | New York, NY | ||||
| Innovimmune Biotherapeutics | Accelerator/Incubator Backed | New York, NY | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Immusoft | Venture Capital-Backed | Seattle, WA |
Inspirna Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Inspirna Patents
Inspirna Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022316200-A1 | Compositions and methods for inhibiting creatine transport as a treatment for cancer | Pending | 20-Jul-2021 | ||
| CA-3225305-A1 | Compositions and methods for inhibiting creatine transport as a treatment for cancer | Pending | 20-Jul-2021 | ||
| EP-4373582-A1 | Compositions and methods for inhibiting creatine transport as a treatment for cancer | Pending | 20-Jul-2021 | ||
| EP-4373582-A4 | Compositions and methods for inhibiting creatine transport as a treatment for cancer | Pending | 20-Jul-2021 | ||
| US-20240180912-A1 | Compositions and methods for inhibiting creatine transport as a treatment for cancer | Pending | 20-Jul-2021 | A61K31/519 |
Inspirna Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Inspirna Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Dreavent | Venture Capital | Minority | ||
| Sands Capital | Growth/Expansion | Minority | ||
| Silicon Valley Bank | Corporation | Minority | ||
| Vivo Capital | Venture Capital | Minority | ||
| Lepu Medical | Corporation | Minority |
Inspirna FAQs
-
When was Inspirna founded?
Inspirna was founded in 2010.
-
Where is Inspirna headquartered?
Inspirna is headquartered in New York, NY.
-
What is the size of Inspirna?
Inspirna has 15 total employees.
-
What industry is Inspirna in?
Inspirna’s primary industry is Drug Discovery.
-
Is Inspirna a private or public company?
Inspirna is a Private company.
-
What is Inspirna’s current revenue?
The current revenue for Inspirna is .
-
How much funding has Inspirna raised over time?
Inspirna has raised $145M.
-
Who are Inspirna’s investors?
Dreavent, Sands Capital, Silicon Valley Bank, Vivo Capital, and Lepu Medical are 5 of 11 investors who have invested in Inspirna.
-
Who are Inspirna’s competitors?
Attune Pharmaceuticals, Innovimmune Biotherapeutics, Sorrento Therapeutics, CytomX Therapeutics, and Immusoft are some of the 24 competitors of Inspirna.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
